Standard Biotools (LAB) Asset Writedowns and Impairment (2011 - 2026)

Standard Biotools (LAB) has 9 years of Asset Writedowns and Impairment data on file, last reported at $696000.0 in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 14.6% year-over-year to $696000.0 in Q1 2026; TTM through Mar 2026 was $3.3 million, a 26.47% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 37.4% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $696000.0, down from $1.5 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for LAB reached as high as $3.5 million in Q2 2022 and fell as low as -$1.1 million in Q3 2022.
• Historically, Asset Writedowns and Impairment has averaged $711125.0 across 5 years, with a median of $580000.0 in 2025.
• Across the five-year window, Asset Writedowns and Impairment sank 94.29% in 2023 and jumped 515.0% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at -$1.1 million in 2022, then soared by 146.31% to $496000.0 in 2023, then grew by 7.46% to $533000.0 in 2024, then soared by 180.11% to $1.5 million in 2025, then plunged by 53.38% to $696000.0 in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $696000.0 in Q1 2026, $1.5 million in Q4 2025, and $615000.0 in Q3 2025.